Having trouble viewing this email? View in your browser.
Invitation to the live Sanofi symposia at ECCMID 2022
Dear healthcare professional,
We hope you enjoyed the ECCMID 2022 hybrid congress as much as we did. In case you did not have a chance to attend the Sanofi integrated symposia or would like to rewatch them, we are delighted to share with you the replays and key take-home messages from our three symposia.
RSV burden: the need for all infant protection
Micro
ESCMID appointed chair: SHALOM BEN-SHIMOL
Session chair: SUSANNA ESPOSITO
PAOLO MANZONI, HEATHER ZAR, OCTAVIO RAMILIO

Invitation to the live Sanofi symposia at ECCMID 2022
replay CLICK HERE TO VIEW THE REPLAY
Key take-home messages:
Rethinking RSV epidemiology, past, present, and future
  • The COVID-19 pandemic has changed the epidemiology of RSV, resulting in a surge of RSV infections, an alteration of the traditional seasonality, and a sharper increase in severity during the peak phases
  • The future epidemiology of RSV is poorly predictable but highlights the need to explore the future to see RSV as a risk in all infants
Reimagining the acute and persistent burden of RSV in all infants
  • RSV represents a substantial acute morbidity and mortality burden globally, particularly in infants and in lower- and lower-middle-income countries
  • Evidence suggests a strong link between RSV and persistent burden of recurrent wheezing
  • Lack of preventive options may have a substantial effect on RSV disease burden
The immunopathogenesis of RSV and challenges in infant immunity
  • Infant immunity poses opportunities for the immunopathogenesis of RSV – limited antibody response, inadequate interferon responses, and increased risk for severe RSV disease
  • Some potential preventative approaches may represent an attractive strategy for RSV prevention in young infants
Influenza vaccination: protection beyond flu
Micro
ESCMID appointed chair: REBECCA JANE COX
Session chair: JOHN PAGET
LEONARD HOFSTRA, ANGEL CHU, STEFANIA MAGGI

Invitation to the live Sanofi symposia at ECCMID 2022
replay CLICK HERE TO VIEW THE REPLAY
Key take-home messages:
Influenza causes additional burden due to broader health impacts including cardiovascular events and the exacerbation of chronic underlying conditions. Thus, vaccination against influenza not only prevents or limits influenza like illness, but also provides additional protection beyond flu – meaning protection from complications. High level of evidence of data as generated for the high-dose influenza vaccine in those 60+ or 65+ years old, is important to demonstrate this protection.
What matters in the fight against COVID-19: how to keep high levels of protection in a multivariant environment?
Micro
ESCMID appointed chair: ROXANA FILIP
Session chair: FEDERICO MARTINÓN-TORRES
SALIM ABDOOL KARIM, ALLISON MCGEER,
BEHAZINE COMBADIERE, SARANYA SRIDHAR

Invitation to the live Sanofi symposia at ECCMID 2022
replay CLICK HERE TO VIEW THE REPLAY
Key take-home messages:
  • COVID’s evolving journey – The rapid evolution of SARS-CoV-2 variants and the waning of immunity obtained from primary vaccination has impacted the evolution of the pandemic.
  • Variants and maintaining protection – SARS-CoV-2 variants of concern exhibit varying degrees of immune escape which can be difficult to predict in future variants.
  • The developing vaccine landscape – Future challenges in vaccine development include providing long-term and broad protection against multiple variants. Such challenges can be surmounted by implementing innovation in vaccine formulations and surveillance to reduce transmission and escape variant emergence.
  • New vaccines: boosting the immune response regardless of the primary vaccination received; how to ensure future protection – Developing new vaccines is a complex process. Consideration should be given to vaccine
more
web Link to the Sanofi profile page


We would like to express our deepest thanks to the faculty and delegates that participated in our symposia and look forward to future conversations.
These contents are for healthcare professionals only. Please consult the prescribing information in your country of practice, as it can vary from country to country. Integrated symposia are not included in main conference CME/CPD credit.
Sanofi logo
© SANOFI  2022 - MAT-GLB-2201589 v1 04/2022
You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.